Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

FDA Grants Priority Review to Beti-Cel for β-thalassemia Requiring Transfusions

November 22nd 2021

The FDA has granted a priority review designation to a biologics license application for betibeglogene autotemcel for the treatment of adult, adolescent, and pediatric patients with β-thalassemia across all genotypes who require regular red blood cell transfusions.

Treatment Landscape Shifts Away From Chemotherapy Toward Targeted Approaches in ALL

November 22nd 2021

Novel approaches with highly active, minimally toxic agents are needed to improve upon traditional chemotherapy and possibly eliminate chemotherapy altogether in the treatment of patients with acute lymphoblastic leukemia.

Variable Chronic GVHD Presentations Stress the Need for Close Symptom Monitoring

November 22nd 2021

Joyce L. Neumann, PhD, APRN, AOCN, BMTCN, FAAN, discusses the variability in cGVHD presentation, key symptoms of the disease in patients with cancer, and how the field is navigating between available therapies.

Treatment Options for Follicular Lymphoma: Second Line and Beyond

November 22nd 2021

Tycel Jovelle Phillps, MD, shares second-line treatment approaches for the management of follicular lymphoma and examines the use of PI3K inhibitors.

Overview of Follicular Lymphoma and Frontline Treatment

November 22nd 2021

Alexey Danilov, MD, and Tycel Jovelle Phillips, MD, provide insight on common signs and symptoms of follicular lymphoma (FL) and factors to consider when selecting first-line therapy.

mRNA COVID-19 Vaccines May Decrease Efficacy in Lymphoid Malignancies

November 19th 2021

Patients with lymphoid malignancies, especially those who have received recent anti-CD20 antibody therapy, have reduced humoral responses to the mRNA COVID-19 vaccines, and as such, should continue to take precautionary measures against COVID-19 infection irrespective of vaccination status.

Quizartinib/Chemo Shows Superior OS Benefit Over Chemo Alone in Newly Diagnosed FLT3-ITD+ AML

November 19th 2021

The addition of quizartinib to chemotherapy resulted in a statistically significant and clinically meaningful improvement in overall survival vs standard chemotherapy alone in patients with newly diagnosed, FLT3-ITD–positive acute myeloid leukemia.

Long-Term Toxicity With Frontline Steroids Remains a Key Consideration of Chronic GVHD Management

November 19th 2021

Corey S. Cutler, MD, MPH, FRCPC, discusses the diagnostic and treatment landscape of chronic graft-vs-host disease.

Mortality Rate Associated With COVID-19 Breakthrough Cases Remains High in Hematologic Malignancies

November 18th 2021

Although mortality rates in patients with hematologic cancers who develop breakthrough COVID-19 cases after vaccination are high, there has been a significant decrease in incidence since vaccines have become available.

The Evolving Treatment Landscape of Chronic GVHD

November 17th 2021

Closing out his discussion on chronic GVHD, Corey Cutler, MD, MPH, FRCPC, discusses belumosudil and how all 3 newly approved agents fit into the evolving treatment landscape.

REACH-3 Trial of Ruxolitinib in Steroid-Refractory Chronic GVHD

November 17th 2021

Expert insight on the study design and results of REACH-3, which tested ruxolitinib in patients with steroid-refractory chronic GVHD.

REACH-2 Trial of Ruxolitinib in Steroid-Refractory Acute GVHD

November 17th 2021

Corey Cutler, MD, MPH, FRCPC, reviews the study design and results of REACH-2, which tested ruxolitinib in patients with steroid-refractory acute GVHD.

An Overview of Treatment Options for Chronic GVHD

November 17th 2021

A comprehensive review of the treatment armamentarium for patients with chronic graft vs host disease.

Prophylactic Strategies in Graft vs Host Disease Management

November 17th 2021

Expert insight on prophylaxis in graft vs host disease, with a focus on specific pharmacologics and the overall efficacy of prophylactic strategies.

An Overview of the Graft vs Host Disease Landscape

November 17th 2021

Corey Cutler, MD, MPH, FRCPC, provides an overview of graft vs host disease and some of the factors that may put patients at higher risk.

Pre-BLA Meeting Held With FDA for Omidubicel in Select High-Risk Hematologic Malignancies

November 12th 2021

Gamida Cell Ltd. has completed a Type B Pre-Biologics License Application meeting with the FDA to discuss the investigational advanced cell therapy omidubicel as a potential therapeutic option for patients with blood cancers who require stem cell transplant.

First-in-class Anti-CD47 Fusion Protein DSP107 Under Investigation in AML and MDS

November 10th 2021

The FDA cleared an investigational new drug application for a phase 1b clinical trial examining DSP107, a first-in-class anti-CD47 fusion protein, in patients with acute myeloid leukemia and myelodysplastic syndrome.

MRD Continues to Show Prognostic Potential in AML and Shape Treatment Decisions

November 3rd 2021

Newer modalities are exploring ways to provide more specificity on the value of minimal residual disease negativity in acute myeloid leukemia, since currently there is little definitive action that can be taken with the marker in clinical practice, according to Naval Daver, MD.

FDA Approval Insights: Brexucabtagene Autoleucel in Relapsed/Refractory B-ALL

November 1st 2021

Dr. Shah discusses the FDA approval of brexucabtagene autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia, key findings from the pivotal ZUMA-3 trial, and next steps with CAR T-cell therapy in the field.

Devimistat Falls Flat in Metastatic Pancreatic Cancer and Relapsed/Refractory AML

October 29th 2021

Devimistat, which is being evaluated in combination with modified FOLFIRINOX in the frontline treatment of patients with metastatic adenocarcinoma of the pancreas, failed to meet the primary end point of overall survival in the phase 3 AVENGER 500 trial.